Durham, NC – According to filings with the U.S. Securities and Exchange Commission, Aerami Therapeutics is raising $15,000,000.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Michael Kaseta played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Aerami Therapeutics

We are committed to developing improved therapies for the treatment of severe respiratory diseases. Our lead asset is inhaled imatinib (AER-901) for the treatment of pulmonary arterial hypertension. Our product development approach combines novel formulations of existing drugs with our inhalation technology for the treatment of severe respiratory diseases with high unmet need.

To learn more about Aerami Therapeutics, visit http://aerami.com/

Contact:
Michael Kaseta, Chief Financial Officer
919-589-7495
mkaseta@aerami.com
https://www.linkedin.com/in/mike-kaseta-b628b83/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved